Astrazeneca (AZN) Income from Continuing Operations (2009 - 2026)
Astrazeneca (AZN) posted quarterly Income from Continuing Operations of 2603000000.0 for Q2 2026, down 9.56% year-over-year from 2878000000.0 in Q2 2025, and down 45.17% quarter-over-quarter from 4747000000.0 in Q1 2026.
Astrazeneca (AZN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Astrazeneca's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 2603000000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 9.56% year-over-year to 2603000000.0; the TTM figure through Jun 2026 stood at 14232000000.0 (up 31.58% YoY), while the FY2025 annual figure was 10767000000.0, up 52.92% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 2603000000.0, down from 4747000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 7002000000.0 in Q4 2023, with the low at 134000000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 2661500000.0 (2023), against an average of 2613666666.67.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 86.3% in 2022, then soared 1658.21% in 2023.
- Astrazeneca's Income from Continuing Operations stood at 654000000.0 in 2022, then jumped by 970.64% to 7002000000.0 in 2023, then slumped by 73.84% to 1832000000.0 in 2024, then surged by 59.88% to 2929000000.0 in 2025, then slipped by 11.13% to 2603000000.0 in 2026.
- Business Quant data shows AZN's Income from Continuing Operations at 2603000000.0 in Q2 2026, 4747000000.0 in Q1 2026, and 2929000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Bn |
| Mar 31, 2026 | 4.75 Bn |
| Dec 31, 2025 | 2.93 Bn |
| Sep 30, 2025 | 3.95 Bn |
| Jun 30, 2025 | 2.88 Bn |
| Mar 31, 2025 | 3.88 Bn |
| Dec 31, 2024 | 1.83 Bn |
| Sep 30, 2024 | 2.22 Bn |
| Jun 30, 2024 | 2.87 Bn |
| Mar 31, 2024 | 3.42 Bn |
| Dec 31, 2023 | 7.00 Bn |
| Sep 30, 2023 | 1.93 Bn |
| Jun 30, 2023 | 2.36 Bn |
| Mar 31, 2023 | 2.72 Bn |
| Dec 31, 2022 | 654.00 Mn |
| Sep 30, 2022 | 202.00 Mn |
| Jun 30, 2022 | 134.00 Mn |
| Mar 31, 2022 | 718.00 Mn |
| Dec 31, 2021 | -926.00 Mn |
| Sep 30, 2021 | -2.35 Bn |